Journal article
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Abstract
BackgroundTrametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametinib in patients with advanced solid tumors who had various degrees of hepatic dysfunction (HD).MethodsAdvanced cancer patients were stratified into 4 HD groups based on Organ Dysfunction Working Group hepatic …
Authors
Voon PJ; Chen EX; Chen HX; Lockhart AC; Sahebjam S; Kelly K; Vaishampayan UN; Subbiah V; Razak AR; Renouf DJ
Journal
Journal of Experimental & Clinical Cancer Research, Vol. 41, No. 1,
Publisher
Springer Nature
Publication Date
12 2022
DOI
10.1186/s13046-021-02236-7
ISSN
0392-9078